CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 81 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $37,934,916 | -8.7% | 1,275,552 | -44.7% | 4.24% | -0.9% |
Q2 2023 | $41,546,155 | +112105.0% | 2,305,558 | 0.0% | 4.28% | -7.5% |
Q1 2023 | $37,027 | -12.2% | 2,305,558 | 0.0% | 4.63% | -1.8% |
Q4 2022 | $42,192 | -99.9% | 2,305,558 | 0.0% | 4.72% | -12.8% |
Q3 2022 | $45,281,000 | +5.3% | 2,305,558 | 0.0% | 5.40% | +7.2% |
Q2 2022 | $42,999,000 | -3.5% | 2,305,558 | +13.6% | 5.04% | +16.5% |
Q1 2022 | $44,552,000 | -22.7% | 2,029,701 | 0.0% | 4.33% | -5.4% |
Q4 2021 | $57,664,000 | +63.1% | 2,029,701 | +20.8% | 4.57% | +108.5% |
Q3 2021 | $35,358,000 | +11.7% | 1,679,701 | 0.0% | 2.19% | +5.7% |
Q2 2021 | $31,662,000 | +93.4% | 1,679,701 | +56.8% | 2.08% | +123.8% |
Q1 2021 | $16,371,000 | +8.3% | 1,071,428 | 0.0% | 0.93% | -2.3% |
Q4 2020 | $15,118,000 | -10.0% | 1,071,428 | 0.0% | 0.95% | -39.4% |
Q3 2020 | $16,789,000 | -10.6% | 1,071,428 | 0.0% | 1.56% | -20.4% |
Q2 2020 | $18,771,000 | – | 1,071,428 | – | 1.97% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |